← SynDRA
SERABELISIB
SynDRA canonical compound SYN0038651 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- PIK3CA
- MTOR
- PIK3CB
- PIK3CD
- PIK3CG
Mechanisms of action (all sources)
- PIK3CA INHIBITOR
- PI3-kinase p110-alpha subunit inhibitor
- MTOR inhibitor
- PIK3CB INHIBITOR
- PIK3CD INHIBITOR
- PIK3CG INHIBITOR
- PI3K inhibitor
Drug classes
Cross-references
Synonyms
- Ink-1117
- MLN-1117
- TAK-117
- AGN-PC-0DB6FL
- INK1117
- MLN1117
- MLN 1117
- INK 1117
- TAK 117
- serabelisibum
- RefChem:182491
- Serabelisib [INN]
- MFCD15146372
- UNII-43J9Q56T3W
- C19H17N5O3
- SERABELISIB [WHO-DD]
- GTPL8969
- orb1304485
- TAK117
- SCHEMBL12928418
- SCHEMBL29382156
- BDBM119531
- EX-A1112
- MLN1117; INK1117
- NSC795384
- s8581
- AKOS030526373
- CCG-268203
- CS-5490
- EBC-520105
- NSC-795384
- NCGC00509943-02
- AC-33667
- AS-73722
- HY-12285
- DB-084944
- INK-1117,MLN-1117,TAK-117
- Serabelisib(TAK-117,INK1117,MLN1117)
- Serabelisib(TAK-117,INK1117,MLN1117)?
Look up SERABELISIB in the interactive SynDRA portal →